<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37497619</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Hidden consequences: Uncovering belimumab's role in the development of <i>Pneumocystis jirovecii</i> pneumonia in a lupus patient.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1230</EndPage><MedlinePgn>1227-1230</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231192334</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND"><i>Pneumocystis jirovecii</i> is an opportunistic fungal organism that can cause fatal pneumonia in immunocompromised individuals. It is a disease associated with CD4+ T cell depletion or high-dose steroids. However, there is increasing evidence that B cell dysfunction may also play a role in this illness.</AbstractText><AbstractText Label="CASE REPORT" NlmCategory="METHODS">A 33-year-old female with SLE, who was maintained on belimumab and low-dose prednisone (2.5&#xa0;mg daily), presented with progressive cough and shortness of breath. She had been on monthly belimumab and prednisone 2.5&#xa0;mg daily for 19&#xa0;months, and her CD4 count was &gt;200/uL, but her CD19+ B cell was &lt;1% due to the belimumab. She developed a persistent cough and progressive dyspnea that did not respond to empiric antibiotic therapy for pneumonia. She went to the hospital for acute worsening of her dyspnea and cough. An extensive workup was performed, including a VATS procedure and surgical biopsy, which gave a definitive diagnosis of PJP. The patient was treated and discharged on trimethoprim-sulfamethoxazole. She made a complete recovery.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our report demonstrates the first confirmed case of pneumocystis jirovecii pneumonia in a patient with B cell depletion due to chronic maintenance therapy with belimumab. Our patient's diagnosis of PJP was unexpected, given her normal CD4+ count and the use of such a low dose of prednisone. We attribute her susceptibility to PJP infection to her profound B cell depletion in response to her belimumab therapy, supporting previous research indicating the importance of CD4+ T cells and B cells in the protective immune response against PJP. This case may help shape future clinical guidelines concerning PJP prophylaxis, particularly in SLE patients with deficient B lymphocytic activity and B cell depletion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9780-5491</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, North Shore University Hospital, New Hyde Park, NY, USA.</Affiliation><Identifier Source="RINGGOLD">24945</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Meggan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hofstra Northwell School of Medicine, Uniondale, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, North Shore University Hospital, New Hyde Park, NY, USA.</Affiliation><Identifier Source="RINGGOLD">24945</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautam-Goyal</LastName><ForeName>Pranisha</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9857-1826</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, North Shore University Hospital, New Hyde Park, NY, USA.</Affiliation><Identifier Source="RINGGOLD">24945</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Hofstra Northwell School of Medicine, Uniondale, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hofstra Northwell School of Medicine, Uniondale, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, North Shore University Hospital, New Hyde Park, NY, USA.</Affiliation><Identifier Source="RINGGOLD">24945</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vikraman</LastName><ForeName>Praveen Kumar</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-6654-9579</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, North Shore University Hospital, New Hyde Park, NY, USA.</Affiliation><Identifier Source="RINGGOLD">24945</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011020" MajorTopicYN="Y">Pneumonia, Pneumocystis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003371" MajorTopicYN="N">Cough</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pneumocystis jirovecii pneumonia</Keyword><Keyword MajorTopicYN="N">belimumab</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37497619</ArticleId><ArticleId IdType="doi">10.1177/09612033231192334</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>